JPWO2020257681A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020257681A5 JPWO2020257681A5 JP2021571689A JP2021571689A JPWO2020257681A5 JP WO2020257681 A5 JPWO2020257681 A5 JP WO2020257681A5 JP 2021571689 A JP2021571689 A JP 2021571689A JP 2021571689 A JP2021571689 A JP 2021571689A JP WO2020257681 A5 JPWO2020257681 A5 JP WO2020257681A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- agonist
- composition
- antigen binding
- psma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024144403A JP2024164199A (ja) | 2019-06-21 | 2024-08-26 | Ｐｓｍａおよびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864999P | 2019-06-21 | 2019-06-21 | |
| US62/864,999 | 2019-06-21 | ||
| PCT/US2020/038786 WO2020257681A1 (en) | 2019-06-21 | 2020-06-19 | Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024144403A Division JP2024164199A (ja) | 2019-06-21 | 2024-08-26 | Ｐｓｍａおよびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022537019A JP2022537019A (ja) | 2022-08-23 |
| JPWO2020257681A5 true JPWO2020257681A5 (https=) | 2023-06-21 |
| JP2022537019A5 JP2022537019A5 (https=) | 2023-06-21 |
| JP7743313B2 JP7743313B2 (ja) | 2025-09-24 |
Family
ID=71528054
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571689A Active JP7743313B2 (ja) | 2019-06-21 | 2020-06-19 | Ｐｓｍａおよびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
| JP2024144403A Pending JP2024164199A (ja) | 2019-06-21 | 2024-08-26 | Ｐｓｍａおよびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024144403A Pending JP2024164199A (ja) | 2019-06-21 | 2024-08-26 | Ｐｓｍａおよびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200399372A1 (https=) |
| EP (1) | EP3986933A1 (https=) |
| JP (2) | JP7743313B2 (https=) |
| KR (1) | KR20220024594A (https=) |
| CN (2) | CN118526580A (https=) |
| AU (1) | AU2020296181A1 (https=) |
| CA (1) | CA3139827A1 (https=) |
| IL (1) | IL289041A (https=) |
| MA (1) | MA56515A (https=) |
| MX (1) | MX2021015271A (https=) |
| WO (1) | WO2020257681A1 (https=) |
| ZA (1) | ZA202109048B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023147784A1 (zh) * | 2022-02-07 | 2023-08-10 | 江苏恒瑞医药股份有限公司 | 特异性结合psma和cd3的抗原结合分子及其医药用途 |
| KR20250010677A (ko) * | 2022-05-16 | 2025-01-21 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-PSMA x 항-CD3 항체를 단독으로 또는 항-PD-1 항체와 병용으로 전이성 거세 저항성 전립선암을 치료하는 방법 |
| WO2025070636A1 (ja) * | 2023-09-26 | 2025-04-03 | ブライトパス・バイオ株式会社 | Ｃｄ３９を標的とする多重特異性抗原結合性分子 |
| CN118086511B (zh) * | 2024-04-25 | 2024-07-09 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | 胃粘膜肠上皮化生亚型生物标志物folh1及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5428156A (en) | 1993-04-02 | 1995-06-27 | Associated Universities, Inc. | Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| SI2501817T2 (sl) | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| UA129760C2 (uk) * | 2013-12-17 | 2025-07-30 | Дженентек, Інк. | Анти-cd3 антитіло та спосіб його застосування |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| EP3131585B1 (en) | 2014-03-19 | 2020-07-15 | Universität Zürich | Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy |
| CN106794264B (zh) * | 2014-06-10 | 2021-03-23 | 3B制药有限公司 | 包含神经降压肽受体配体的缀合物及其用途 |
| JP6689836B2 (ja) * | 2014-10-16 | 2020-04-28 | ザ ユニバーシティー オブ メルボルンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｍｅｌｂｏｕｒｎｅ | 新規なイメージング組成物およびその使用 |
| JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| LT3353212T (lt) * | 2015-09-23 | 2021-12-27 | Regeneron Pharmaceuticals, Inc. | Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas |
| KR20180096789A (ko) * | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| EP3548515B1 (en) * | 2016-12-01 | 2026-01-21 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| WO2018114754A1 (en) | 2016-12-19 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with targeted 4-1bb (cd137) agonists |
| AU2017384126B2 (en) | 2016-12-20 | 2025-01-23 | F. Hoffmann-La Roche Ag | Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists |
| US10174122B2 (en) * | 2017-01-06 | 2019-01-08 | Eutilex Co., Ltd. | Anti-human 4-1BB antibodies and uses thereof |
| WO2020028444A1 (en) * | 2018-07-30 | 2020-02-06 | University Of Southern California | Improving the efficacy and safety of adoptive cellular therapies |
-
2020
- 2020-06-19 CN CN202410406265.5A patent/CN118526580A/zh active Pending
- 2020-06-19 MA MA056515A patent/MA56515A/fr unknown
- 2020-06-19 AU AU2020296181A patent/AU2020296181A1/en active Pending
- 2020-06-19 KR KR1020227001447A patent/KR20220024594A/ko active Pending
- 2020-06-19 JP JP2021571689A patent/JP7743313B2/ja active Active
- 2020-06-19 EP EP20737787.0A patent/EP3986933A1/en active Pending
- 2020-06-19 CN CN202080045496.8A patent/CN114025802B/zh active Active
- 2020-06-19 WO PCT/US2020/038786 patent/WO2020257681A1/en not_active Ceased
- 2020-06-19 MX MX2021015271A patent/MX2021015271A/es unknown
- 2020-06-19 US US16/906,943 patent/US20200399372A1/en active Pending
- 2020-06-19 CA CA3139827A patent/CA3139827A1/en active Pending
-
2021
- 2021-11-12 ZA ZA2021/09048A patent/ZA202109048B/en unknown
- 2021-12-15 IL IL289041A patent/IL289041A/en unknown
-
2024
- 2024-08-26 JP JP2024144403A patent/JP2024164199A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102349056B1 (ko) | Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법 | |
| JP2021513844A5 (https=) | ||
| JP2022078265A (ja) | 肺癌の処置のための抗ｐｄ－１抗体 | |
| JP2021519076A5 (https=) | ||
| JP2020534250A5 (https=) | ||
| CN102174108A (zh) | 内在化抗-cd74抗体和使用方法 | |
| JP2002515460A (ja) | 二重特異性抗ｈｌａクラスｉｉ不変鎖ｘ抗病原体抗体を使用した治療 | |
| JP2012500006A5 (https=) | ||
| JP2025026572A5 (https=) | ||
| CN114206937A (zh) | 18f放射性标记的生物分子 | |
| JP2020534300A5 (https=) | ||
| TW201536319A (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| JP2023516906A (ja) | 分子連結法または分子工学のためのタンデムリピートがん標的化ペプチドおよびがんセラノスティクスにおけるその使用 | |
| JPWO2019191728A5 (https=) | ||
| JPWO2020257681A5 (https=) | ||
| JPWO2020257604A5 (https=) | ||
| WO2001052889A1 (fr) | Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers | |
| JP2020509745A5 (https=) | ||
| RU2021132847A (ru) | Применение биспецифических антигенсвязывающих молекул, которые связывают psma и cd3, в комбинации с костимуляцией 4-1bb | |
| JPWO2019217455A5 (https=) | ||
| RU2021132494A (ru) | Применение биспецифических антигенсвязывающих молекул, которые связывают muc16 и cd3, в комбинации с костимуляцией 4-1bb | |
| JPWO2023081752A5 (https=) | ||
| Varterasian | Advances in the biology and treatment of multiple myeloma | |
| RU2024117785A (ru) | Применение биспецифических антигенсвязывающих молекул, которые связывают muc16 и cd3, в комбинации с костимуляцией 4-1bb | |
| JPWO2023133388A5 (https=) |